In August 2025, semaglutide became the first GLP-1 medication to receive FDA approval specifically for treating MASH
Personal and Familial Malignancy History in Patients with Malignant Peripheral Nerve Sheath Tumors with a Focus on Sporadic Tumors
With a focus on customized and responsive pharmaceuticals, ongoing advancements in drug delivery systems provide new avenues for more effective therapy with fewer side effects
Understanding your genetic peptide sensitivity empowers personalized treatment timing that aligns with your biology rather than a one-size-fits-all schedule
a , Cryo-EM micrograph of the activated GLP-1RG s complex
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T